Advertisement
Screener

Bicara Therapeutics Inc. (BCAX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

1.7 / 5 stars · 4/12 Roast Me

Bicara Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

Bicara Therapeutics Inc. (BCAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 435.32 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-11

  • Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 435.32K shares, a 648.66% increase year-over-year.
  • Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 0.00 shares.
  • Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 132.69K shares, a 190.14% increase year-over-year.
  • Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares.
  • Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 190.84K shares, a 16.91% increase from fiscal 2024.
  • Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 163.23K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month
2026-06-30435.32K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
435.32K shares
10-Q · filed 2026-08-11
568.02K shares
derived: sum of 3 quarters · filed 2026-08-11
568.02K shares
derived: sum of 4 quarters · filed 2026-08-11
2026-03-310.00 shares
10-Q · filed 2026-05-11
132.69K shares
derived: sum of 2 quarters · filed 2026-05-11
132.69K shares
derived: sum of 3 quarters · filed 2026-05-11
190.84K shares
derived: sum of 4 quarters · filed 2026-05-11
2025-12-31132.69K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
132.69K shares
derived: sum of 2 quarters · filed 2026-03-30
190.84K shares
derived: sum of 3 quarters · filed 2026-03-30
190.84K shares
10-K · filed 2026-03-30
2025-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
58.15K shares
derived: sum of 2 quarters · filed 2025-11-10
58.15K shares
10-Q · filed 2025-11-10
103.88K shares
derived: sum of 4 quarters · filed 2025-11-10
2025-06-3058.15K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
58.15K shares
10-Q · filed 2025-08-12
103.88K shares
derived: sum of 3 quarters · filed 2025-08-12
2025-03-310.00 shares
10-Q · filed 2025-05-13
45.73K shares
derived: sum of 2 quarters · filed 2025-05-13
2024-12-3145.73K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
163.23K shares
10-K · filed 2025-03-27
2024-09-30117.49K shares
10-Q · filed 2024-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Kardigan, Inc. (KARD)United States$1.346B
Avalyn Pharma Inc. (AVLN)United States$1.267B
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
HARROW, INC. (HROW)United States$1.240B-42.77
OPKO HEALTH, INC. (OPK)United States$1.220B-15.59
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
Jaguar Health, Inc. (JAGX)United States$1.184B